Table 2.

Univariate and multivariate analysis of prognostic factors in total patients.

Variable	Univariate analysis		Multivariate analysis
	Median OS, months (95% CI)	p value	Hazard ratio (95% CI)	p value
Treatment		<0.001		0.001
Apatinib	7.0 (5.8–8.2)		Ref
supportive care	4.0 (2.9–5.1)		2.837 (1.568–5.132)
Age		0.409	–	–
<52	5.0 (3.9–6.1)
⩾52	5.0 (3.6–6.4)
Sex		0.536	–	–
Male	5.0 (3.9–6.1)
Female	5.0 (1.3–8.7)
Cirrhosis		0.708	–	–
Absent	5.0 (3.9–6.1)
Present	6.0 (1.7–10.3)
Liver tumor load		<0.001		<0.001
<50%	13.0 (7.0–18.9)		Ref
⩾50%	4.0 (3.7–4.3)		3.364 (2.147–6.144)
Number of tumors		0.004		0.470
>5	5.0 (4.1–5.9)		Ref
1–5	13.0 (10.1–15.9)		0.689 (0.251–1.893)
PVTT		<0.001		0.410
Absent	8.0 (4.3–11.7)		Ref
Present	5.0 (4.5–5.5)		1.500 (0.572–3.933)
Extrahepatic spread		<0.001		0.543
Present	9.0 (2.4–15.6)		Ref
Absent	4.0 (3.3–4.7)		0.808 (0.406–1.608)
ECOG		0.807	–	–
0–1	5.0 (3.7–6.3)
2	5.0 (2.7–7.3)
Child-Pugh class		<0.001		0.323
A	7.0 (6.0–7.9)		Ref
B	3.5 (3.1–3.9)		1.505 (0.669–3.385)
Ascites		0.001		0.284
Absent	6.0 (5.0–6.9)		Ref
Present	4.0 (3.3–4.7)		1.518 (0.707–3.260)
Albumin (g/l)		0.024		0.737
<35	4.0 (3.3–4.7)		Ref
⩾35	6.0 (4.8–7.2)		0.913 (0.537–1.552)
AFP level		0.322	–	–
<400	7.0 (6.3–7.7)
⩾400	5.0 (4.5–5.5)
GGT (U/l)		0.608	–	–
>100	5.0 (3.8–6.2)
⩽100	6.0 (4.8–7.2)
ALT (U/l)		0.626	–	–
⩽40	5.0 (3.8–6.2)
>40	6.0 (4.6–7.4)
Bilirubin (μmol/l)		0.629	–	–
⩽20	5.0 (4.2–5.8)
>20	6.0 (4.6–7.4)

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GGT, γ-glutamyl transpeptidase; OS, overall survival; PVTT, portal vein tumor thrombosis.